During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Rajat Bannerji, Rutgers Cancer Institute of New Jersey, New Brunswick, US. We asked: Where might the bispecific antibody REGN1979 fit within the treatment pathway of patients with relapsed/refractory non-Hodgkin lymphoma?
Rajat Bannerji discussed the results of the dose-escalation stage of the first-in-human study phase I clinical trial. This CD20xCD3 antibody was well tolerated with no unexpected toxicities and early evidence of activity in follicular lymphoma, DLBCL, MZL and other.
